CATHERINE BAILEY: Open Payments
NPI 1316912587 · JACKSONVILLE, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$915 in 42 payments from 14 companies in 2025. Trend: 2023 $797 · 2024 $595 · 2025 $915
Food & beverage: $915
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 10 | $168 |
| Madrigal Pharmaceuticals | 3 | $158 |
| Gilead Sciences, Inc. | 6 | $127 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 4 | $78 |
| Ipsen Biopharmaceuticals, Inc | 3 | $74 |
| Janssen Biotech, Inc. | 4 | $60 |
| Novo Nordisk Inc | 2 | $47 |
| GENZYME CORPORATION | 2 | $44 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $39 |
| Lilly USA, LLC | 2 | $34 |
Products named: REZDIFFRA, RINVOQ, XIFAXAN, IQIRVO, TREMFYA, LINZESS, Wegovy, DUPIXENT.
Industry payments across FL — which companies pay providers there.
